한글목차

SKYSONA의 주요 성장 촉진요인

1. 시장 점유율 확대 및 신규 환자 치료 시작

• SKYSONA는 미국에서 조기 활동성 대뇌형 부신백질이영양증(CALD)에 대해 승인된 최초의 유전자 치료제 중 하나로 주목받고 있으며, 기존에 치료법이 없었던 환자군(4-17세 남자아이, 이식 가능한 HLA 적합 공여자가 없는 환자)에게 단회 투여로 치료옵션을 제공합니다. 치료 옵션을 제공합니다.
• CALD의 초희귀성과 엄격한 자격기준으로 인해 신규 환자 수는 본질적으로 제한적입니다. 채용은 유전자 치료를 시행할 수 있는 전문 치료 센터에 집중되어 있습니다.
• 또한 스카이소나의 상업적 활용은 대체할 수 있는 줄기세포 이식 공여자가 없는 환자에게만 적용하도록 제한하는 강화된 규제 기준에 의해 형성되고 있으며, 이는 신규 환자 치료 시작 속도에 영향을 미칠 수 있습니다.

2. 중요한 적응증으로 확대

• 대뇌형 부신백질이영양증(CALD) : SKYSONA는 ABCD1 유전자의 돌연변이로 인해 발생하는 희귀하고 쇠약하며 종종 치명적인 신경퇴행성 질환인 조기 활동성 CALD를 앓고 있는 4-17세 남자아이의 신경학적 진행 지연을 적응증으로 하고 있습니다.
• 본 치료법은 환자 자신의 줄기세포를 유전자 조작하여 기능성 ABCD1 유전자 사본을 추가함으로써 뇌내 초장쇄 지방산의 분해를 돕는 단회 투여 자가 조혈모세포 유전자 치료법입니다.
• SKYSONA의 작용기전은 적합 공여자를 필요로 하고 심각한 위험을 수반하는 기존의 표준 치료인 동종 줄기세포 이식과는 다른 치료 옵션을 제공합니다.
• 적응증은 초기 활동성 CALD에 국한되어 있으며, 승인 후의 연구 결과를 바탕으로 현재 안전성과 사용방법의 정교화에 초점을 맞춘 적응증 조정이 이루어지고 있습니다.

3. 지역적 확장

• 스카이소나는 2022년 미국 FDA로부터 신속 승인을 받아 미국내 인증된 치료기관을 통해 시판되고 있습니다.
• 유럽연합(EU)에서는 2021년 판매 승인을 받았으나, 이후 상업적 이유로 승인권자가 신청을 철회하여 현재 유효한 EU 판매 승인은 존재하지 않습니다.
• 미국 외 지역에서의 규제 당국의 승인과 접근성 확대는 여전히 제한적이며, 이 약물의 전문적 특성과 모니터링 요건을 고려할 때, 세계 출시 확대는 규제 당국의 승인과 상업적 타당성 모두에 달려 있습니다.

4. 신규 적응증 승인

• SKYSONA는 2022년 9월 최초 가속 승인 이후, 초기 활동성 CALD에서 신경학적 진행 지연 이외의 적응증을 FDA로부터 승인받지 못했으며, 안전성 데이터를 바탕으로 적응증을 구체화하고 있습니다.
• 현재로서는 다른 질병이나 연령층으로의 확대보다는 주로 안전성에 대한 표시와 환자 자격에 대한 규제 대응에 중점을 두고 있습니다.

5. 강력한 수량 모멘텀

• SKYSONA는 초희귀 환자군이기 때문에 일반적인 만성질환 치료제의 양적 성장세와는 다른 양상을 보이고 있습니다. 채택은 광범위한 처방 증가가 아니라 신생아 선별 검사 및 소아 신경학 네트워크를 통한 적격 환자 식별에 의존하고 있습니다.
• 적격 환자 수가 제한적이고, 안전성에 대한 규제 당국의 신중한 태도가 강화되고 있으며, 실제 임상에서 치료 건수는 아직은 미미한 수준입니다.
• 또한 규제 당국이 효과 확인 및 리스크 모니터링을 위해 요구하는 장기 추적 조사도 임상 사용 패턴에 영향을 미치고 수량에 영향을 미치고 있습니다.

6. 경쟁 우위 및 시장 동향

• SKYSONA의 단회 투여 유전자 치료는 공여자 적합성이 필요하고 이식편대숙주병 등의 위험을 수반하는 표준 동종 줄기세포 이식에 비해 뚜렷한 가치 제안을 제공합니다.
• 이 약은 기능적 ABCD1 유전자 복사본을 도입하여 CALD의 근본적인 유전적 원인에 작용하여 증상 치료뿐만 아니라 진행을 지연시키는 것을 목표로 하고 있습니다.
• 신생아 선별검사 확대, 정밀의료, 유전자 치료의 확산 등 희귀질환 치료의 광범위한 추세는 인식 개선과 조기 진단을 촉진하고, 향후 대상 환자 증가로 이어질 수 있습니다.
• 그러나 규제 당국의 감시 강화와 혈액 악성 종양 위험과 관련된 안전성 우려는 스카이소나를 다른 유전자 치료제와 차별화하고 시장의 신뢰와 보험사의 의사결정에 영향을 미칠 수 있습니다.

스카이소나(SKYSONA)의 주요 7개국(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에 대해 조사 분석했으며, 각국 시장 규모와 예측, 연구개발(R&D) 활동, 경쟁 구도 등의 정보를 전해드립니다.

목차

제1장 리포트의 개요

제2장 부신백질이영양증 등의 승인된 적응증에서 SKYSONA의 개요

제3장 SKYSONA의 경쟁 상황(출시 치료법)

제4장 경쟁 구도(후기 단계의 새로운 SKYSONA 요법)

제5장 SKYSONA 시장 평가

제6장 SKYSONA SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

Key Factors Driving SKYSONA Growth

1. Market Share Gains and New Patient Starts

• SKYSONA has the distinction of being one of the first gene therapies approved in the US for early, active cerebral adrenoleukodystrophy (CALD), offering a one-time treatment option for a previously untreated patient segment (boys 4-17 years without an available HLA-matched donor for transplant).
• Given the ultra-rare nature of CALD and highly specific eligibility criteria, patient starts are inherently limited; adoption has been concentrated at specialized treatment centers capable of administering gene therapy.
• SKYSONA's commercial use is further shaped by tightened regulatory criteria that restricts eligible patients to those without alternative stem cell transplant donors, which may affect the pace of new patient starts.

2. Expansion Across Key Indications

• Cerebral Adrenoleukodystrophy (CALD): SKYSONA is indicated to slow neurological decline in boys aged 4-17 years with early, active CALD - a rare, debilitating, and often fatal neurodegenerative condition caused by mutations in the ABCD1 gene.
• The therapy is a one-time autologous hematopoietic stem cell gene therapy, where a patient's own stem cells are genetically modified to add functional copies of the ABCD1 gene to help break down very long-chain fatty acids in the brain.
• SKYSONA's mechanism offers a distinct treatment alternative to allogeneic stem cell transplantation - the previous standard of care that requires a matched donor and carries significant risks.
• There are no broader indications beyond early, active CALD, and label adjustments now focus on safety and refined use due to post-approval findings.

3. Geographic Expansion

• SKYSONA was initially granted accelerated approval by the US FDA in 2022 and became commercially available through qualified treatment centers in the United States.
• In the European Union, although SKYSONA received a marketing authorization in 2021, the holder withdrew it later for commercial reasons, so there is no current active EU marketing authorization.
• Regulatory and access expansion outside the US remains constrained; broader global launches depend on both regulatory approvals and commercial viability given the drug's specialized nature and surveillance requirements.

4. New Indication Approvals

• Since its initial accelerated approval in September 2022, SKYSONA has not gained additional FDA-approved indications beyond slowing neurological progression in early, active CALD, and its indication has been refined following safety data.
• Regulatory actions have focused largely on safety labeling and patient eligibility rather than expansion into other disease types or age groups at this time.

5. Strong Volume Momentum

• Due to ultra-rare patient populations, SKYSONA's volume momentum differs from typical chronic therapy trends; adoption hinges on identification of eligible patients via newborn screening and pediatric neurology networks rather than broad prescription growth.
• Real-world treatment numbers remain modest because of limited eligible populations and increased regulatory caution around safety.
• Volume momentum is also influenced by long-term follow-up studies required by regulators to confirm benefits and monitor risks, affecting clinical utilization patterns.

6. Competitive Differentiation and Market Trends

• SKYSONA's single-administration gene therapy offers a distinct value proposition over standard allogeneic stem cell transplant, which requires a donor match and carries risks like graft-versus-host disease.
• The drug's inclusion of functional ABCD1 gene copies targets the underlying genetic cause of CALD, aiming to slow progression rather than only addressing symptoms.
• Broader trends in rare disease care - including expanded newborn screening, precision medicine, and gene therapy adoption - support awareness and earlier diagnosis, potentially increasing the pool of eligible patients over time.
• However, heightened regulatory scrutiny and safety concerns related to hematologic malignancy risk differentiate SKYSONA from some other gene therapies and may influence market confidence and payer decisions.

SKYSONA Recent Developments

• Safety-Related Regulatory Actions (2024-2025): The US FDA has updated SKYSONA's labeling and indications due to post-approval reports of hematologic malignancies (including myelodysplastic syndrome and acute myeloid leukemia) in treated patients, resulting in tighter access criteria. The therapy is now recommended only for patients without available alternative treatments or suitable HLA-matched stem cell donors.
• Post-Approval Safety Monitoring: The FDA continues to investigate the risk of hematologic malignancy associated with SKYSONA and mandates long-term, prospective safety follow-up studies to assess the incidence and ensure appropriate monitoring protocols.

"SKYSONA Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of SKYSONA for approved indication like Adrenoleucodystrophy in the 7MM. A detailed picture of SKYSONA's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the SKYSONA for approved indications. The SKYSONA market report provides insights about SKYSONA's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current SKYSONA performance, future market assessments inclusive of the SKYSONA market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of SKYSONA sales forecasts, along with factors driving its market.

SKYSONA Drug Summary

SKYSONA (Elivaldogene autotemcel) is an autologous hematopoietic stem cell-based gene therapy indicated to slow the progression of neurologic dysfunction in boys aged 4-17 years with early, active cerebral adrenoleukodystrophy (CALD), a severe X-linked genetic disorder caused by ABCD1 gene mutations leading to deficient adrenoleukodystrophy protein (ALDP) and accumulation of very long-chain fatty acids (VLCFAs) that trigger brain inflammation and demyelination. The therapy involves harvesting the patient's own CD34+ hematopoietic stem cells via mobilization and apheresis (target >=12 X 10^6 cells/kg), transducing them ex vivo with a lentiviral vector (Lenti-D) carrying functional ABCD1 cDNA to express ALDP, followed by myeloablative conditioning and single intravenous infusion of a minimum dose of >=5.0 X 10^6 CD34+ cells/kg over <60 minutes, without an in-line filter. Post-infusion, the modified stem cells engraft in the bone marrow, differentiate into myeloid cells (e.g., monocytes) that produce and secrete functional ALDP to degrade VLCFAs, cross-correcting affected cells and stabilizing neurologic function as measured by Neurologic Function Score (NFS <=1 at baseline) and gadolinium-enhanced MRI Loes scores of 0.5-9, particularly in patients lacking an HLA-matched allogeneic donor. The report provides SKYSONA's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the SKYSONA Market Report

The report provides insights into:

• A comprehensive product overview including the SKYSONA MoA, description, dosage and administration, research and development activities in approved indication like Adrenoleucodystrophy.
• Elaborated details on SKYSONA regulatory milestones and other development activities have been provided in SKYSONA market report.
• The report also highlights SKYSONA's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The SKYSONA market report also covers the patents information, generic entry and impact on cost cut.
• The SKYSONA market report contains current and forecasted SKYSONA sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The SKYSONA market report also features the SWOT analysis with analyst views for SKYSONA in approved indications.

Methodology:

The SKYSONA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SKYSONA Analytical Perspective by DelveInsight

• In-depth SKYSONA Market Assessment

This SKYSONA sales market forecast report provides a detailed market assessment of SKYSONA for approved indication like Adrenoleucodystrophy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted SKYSONA sales data uptil 2034.

• SKYSONA Clinical Assessment

The SKYSONA market report provides the clinical trials information of SKYSONA for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

SKYSONA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

SKYSONA Market Potential & Revenue Forecast

• Projected market size for the SKYSONA and its key indications
• Estimated SKYSONA sales potential (SKYSONA peak sales forecasts)
• SKYSONA Pricing strategies and reimbursement landscape

SKYSONA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• SKYSONA Market positioning compared to existing treatments
• SKYSONA Strengths & weaknesses relative to competitors

SKYSONA Regulatory & Commercial Milestones

• SKYSONA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

SKYSONA Clinical Differentiation

• SKYSONA Efficacy & safety advantages over existing drugs
• SKYSONA Unique selling points

SKYSONA Market Report Highlights

• In the coming years, the SKYSONA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The SKYSONA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SKYSONA's dominance.
• Other emerging products for Adrenoleucodystrophy are expected to give tough market competition to SKYSONA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SKYSONA in approved indications.
• Analyse SKYSONA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted SKYSONA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SKYSONA in approved indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of SKYSONA? How strong is SKYSONA's clinical and commercial performance?
• What is SKYSONA's clinical trial status in each individual indications such as Adrenoleucodystrophy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SKYSONA Manufacturers?
• What are the key designations that have been granted to SKYSONA for approved indications? How are they going to impact SKYSONA's penetration in various geographies?
• What is the current and forecasted SKYSONA market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of SKYSONA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SKYSONA for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is SKYSONA? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. SKYSONA Overview in approved indications like Adrenoleucodystrophy

• 2.1. Product Detail
• 2.2. SKYSONA Clinical Development
  • 2.2.1. SKYSONA Clinical studies
  • 2.2.2. SKYSONA Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. SKYSONA Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging SKYSONA Therapies)

5. SKYSONA Market Assessment

• 5.1. SKYSONA Market Outlook in approved indications
• 5.2. 7MM Analysis
  • 5.2.1. SKYSONA Market Size in the 7MM for approved indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. SKYSONA Market Size in the United States for approved indications
  • 5.3.2. SKYSONA Market Size in Germany for approved indications
  • 5.3.3. SKYSONA Market Size in France for approved indications
  • 5.3.4. SKYSONA Market Size in Italy for approved indications
  • 5.3.5. SKYSONA Market Size in Spain for approved indications
  • 5.3.6. SKYSONA Market Size in the United Kingdom for approved indications
  • 5.3.7. SKYSONA Market Size in Japan for approved indications

6. SKYSONA SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options